Biguanides and sulfonylureas are by far the most heavily prescribed type 2 diabetes (T2D) drug classes. However, several branded agents are jostling for position as second- and third-line treatment options. Availability of multiple effective therapies from several classes combined with variations in prescribed combinations of drugs, physician preference for specific insulin regimens, and the launch of biosimilar insulins create a challenging market for developers.
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that you can create specific messaging around these treatment dynamics to more effectively increase or defend your market position.
Markets Covered: United States
Primary Research Info
Type 2 Diabetes Current Treatment: Physician Insights is a primary market research study, evaluating physician self-reported prescribing and treatment practices for type 2 diabetes. E-mail invitations were sent to endocrinologists and PCPs to participate in an online survey. Fifty endocrinologists and 50 PCPs completed the survey, which took approximately 30 minutes to complete. Fieldwork occurred in July 2018. To qualify, respondents met the following screening criteria:
After meeting the screening criteria, respondents were directed to an online survey, and respondents were paid an honorarium for their participation. Statistical significance testing was done when appropriate, including anticipated versus current allocations, subgroups, and brands.
Key companies: Sanofi, Novo Nordisk, Boehringer Ingelheim, Eli Lilly, AstraZeneca, Janssen, Merck & Co.
Key drugs: metformin, Lantus, Levemir, Toujeo, Tresiba, Basaglar, NovoLog, Humalog, Apidra, Ozempic, Victoza, Trulicity, Januvia, Jardiance, Invokana, Farxiga.